Business Context and Reporting Period
Company: QT Imaging Holdings, Inc. (QTI)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: QT Imaging is a medical device company developing and commercializing the QT Breast Scanner, a Class II FDA-cleared device that uses low-energy sound waves for 3D breast imaging without radiation or compression. The company is transitioning from a hardware manufacturer to a precision imaging platform combining hardware, software, and cloud-based AI modules.
Key Milestones:
- Uplisted from OTCQB to Nasdaq Capital Market on January 28, 2026.
- Received FDA 510(k) clearance for an enhanced scanner configuration (March 2026) and a new Category III CPT code (X579T) effective January 1, 2027.
- Secured exclusive distribution agreements in the U.S. (NXC), Saudi Arabia (Gulf Medical), and UAE (Al Naghi).
- Entered into a manufacturing agreement with Canon Medical Systems Corporation (CMSC).
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $18,925 | $4,879 |
| Cost of Revenue | $10,341 | $2,239 |
| Gross Profit | $8,584 | $2,640 |
| Gross Margin | 45.4% | 54.1% |
| Net Loss | $(21,083) | $(8,985) |
| Operating Cash Flow | $(8,959) | $(10,033) |
| Cash and Equivalents (Year End) | $10,412 | $1,172 |
| Accumulated Deficit | $(53,024) | $(31,941) |
Debt and Liquidity:
- Long-Term Debt: $10.1 million principal under the Lynrock Lake Term Loan (maturity March 2027). Outstanding balance net of discount was $0.7 million as of Dec 31, 2025.
- Related Party Notes: $3.9 million outstanding (2020 Notes and Working Capital Note).
- Liquidity: Management believes cash on hand, recent PIPE proceeds, and expected revenue from Minimum Order Quantities (MOQs) are sufficient to fund operations for at least 12 months.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 288% to $18.9 million, driven by the sale of 40 QT Breast Scanners in 2025 compared to 12 in 2024, largely due to MOQs under the Amended NXC Distribution Agreement.
- Gross Margin Compression: Gross margin decreased from 54% to 45% due to the sale of higher-cost Model B scanners, initial units manufactured by Canon, and a $1.7 million allocation of overhead from SG&A to Cost of Revenue.
- Net Loss Expansion: Net loss widened to $21.1 million from $9.0 million. This was primarily driven by non-cash expenses including a $6.6 million loss on the issuance of the Lynrock Lake Term Loan, $2.2 million in debt extinguishment/modification charges, and a $3.6 million change in fair value of warrant liabilities.
- Operating Expenses: SG&A decreased 21% to $9.1 million, primarily due to a $4.3 million reduction in transaction expenses related to the 2024 Business Combination, partially offset by increased employee compensation.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Commercialization: The company is executing a hybrid commercialization model in the U.S. via NXC and expanding internationally into the GCC region (Saudi Arabia, UAE) with committed MOQs totaling over $63 million in potential revenue through 2028.
- Reimbursement: Successfully secured a new Category III CPT code (X579T) to facilitate payer education and reimbursement, with an effective date of January 1, 2027.
- Manufacturing: Scaling production through a partnership with Canon Medical Systems Corporation to meet growing demand.
- Profitability: The company has a history of significant losses and negative cash flow. It may never achieve profitability.
- Capital Requirements: Continued reliance on equity and debt financing; failure to raise capital could force reduction of operations.
- Regulatory & Reimbursement: Future revenue depends on maintaining FDA clearances and securing broader third-party payer reimbursement beyond the new Category III code.
- Geopolitical: Operations in the Middle East (Saudi Arabia, UAE) expose the company to risks from regional conflicts and instability.
- Concentration: Significant revenue concentration with a single distributor (NXC) in the U.S.
Investor Verification Checklist
- Debt Covenants: Verify compliance with Lynrock Lake Term Loan covenants, noting the company obtained waivers for Q1-Q3 2025 non-compliance.
- Warrant Liability: Review the impact of the $3.6 million change in fair value of warrant liabilities on net loss and the potential for future volatility.
- MOQ Execution: Monitor the ability of distribution partners (NXC, Gulf Medical, Al Naghi) to meet Minimum Order Quantities, which are critical to the company's liquidity projections.
- Reimbursement Status: Track the adoption of the new CPT code X579T by payers starting January 2027 and the status of the New Technology APC application with CMS.
- Manufacturing Transition: Assess the ramp-up of Canon Medical Systems Corporation as the exclusive manufacturer and the associated cost implications on gross margins.